English

Polaris Pharmaceuticals steps into mRNA technology and actively integrates macromolecular pharmaceutical technology

Multinational biotech company Polaris signed an industry sponsored research agreement with UC Irvine’s (UCI) Vaccine Research and Development Center to fund “Fluvid,” a universal messenger RNA (mRNA) influenza and coronavirus vaccine. Polaris will use the vaccine technology to increase development of vaccines and cancer treatments with the goal being the first company to make mRNA technology more accessible in …

Polaris Pharmaceuticals steps into mRNA technology and actively integrates macromolecular pharmaceutical technology Read More »

Polaris Announces Dr. Philip Felgner Joins the Team

Polaris Pharmaceuticals (6550TW) announced today that Dr. Philip Felgner of the University of California, Irvine will officially join the Polaris Technical Advisory Board on September 1. CEO Mr. Chen said that Dr. Felgner will bring his decades of experience in mRNA technology and related contacts to Polaris, which will bring substantial and timely benefits to …

Polaris Announces Dr. Philip Felgner Joins the Team Read More »

Polaris Announces Dr. Yali Tsai Joins the Team

Polaris Pharmaceuticals announced today that Dr. Yali Tsai has joined Polaris as Vice President of Gene Delivery Technology. With over 25 years of hands-on experience in drug delivery technology and manufacturing, Dr. Tsai has developed a wide range of drugs, including injectable drugs, ophthalmic drugs and skin drugs, and has extensive experience in the development of specialty dosage forms such as microlipids, nanoemulsions and suspension particles.

Polaris Announces Launch of World’s First Phase III Clinical Trial of Genetic Markers for Liver Cancer

Polaris Pharmaceuticals (6550TW) held its 2021 Annual Meeting of Shareholders on (8/23) and announced that it will initiate the world’s first Phase III clinical trial of a single drug for liver cancer screened by genetic biomarkers. The Polaris research and development team analyzed the genes of patients who had participated in liver cancer clinical trials …

Polaris Announces Launch of World’s First Phase III Clinical Trial of Genetic Markers for Liver Cancer Read More »

Polaris Phase II Soft Tissue Sarcoma Trial Receives Attention with ASCO Invitation to Present Results

Polaris Group Polaris Pharmaceuticals-KY(6550TW) announces, Due to the impressive results of the Phase II clinical trial in soft tissue tumors, the trial host has been invited to give a live presentation in the most prestigious “oral presentation” format at the 2021 American Society for Clinical Oncology (ASCO). The clinical trial involved four major medical centers …

Polaris Phase II Soft Tissue Sarcoma Trial Receives Attention with ASCO Invitation to Present Results Read More »

Scroll to Top